Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC
المؤلفون المشاركون
Gal, Omer
Dudnik, Elizabeth
Rotem, Ofer
Finkel, Inbar
Peretz, Idit
Zer, Alona
Mandel, Jacob
Amiel, Alexandra
Siegal, Tali
Bar, Jair
Lobachov, Anastasiya
Yust, Shlomit
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-09-03
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Central nervous system (CNS) metastases occur frequently in oncogene-driven non-small cell lung cancer (NSCLC).
Standard treatment approaches can potentially delay systemic treatment (surgical intervention) or result in neurocognitive impairment (radiotherapy).
Recently, next-generation tyrosine kinase inhibitors (TKIs) have demonstrated remarkable intracranial activity.
However, most clinical trials did not enroll patients suffering neurological symptoms.
Our study aimed to assess the CNS activity of targeted therapies in this patient population.
We present a case series of nine NSCLC patients with either EGFR mutation or ALK rearrangement and symptomatic CNS metastases that were treated with TKIs.
Clinicopathological characteristics, treatment, and outcomes were analyzed.
Most patients presented with symptomatic CNS metastases at time of metastatic disease presentation (6/9).
Additionally, the majority of patients had leptomeningeal disease (6/9) and multiple parenchymal metastases.
Patients presented with a variety of CNS symptoms with the most common being nausea, vomiting, headache, and confusion.
Most patients (6/9) responded rapidly both clinically and radiographically to the targeted treatment, with a marked correlation between systemic and intracranial radiographic response.
In conclusion, upfront use of next-generation TKIs in patients with oncogene-driven NSCLC with symptomatic CNS metastases is associated with reasonable intracranial activity and represents a valuable treatment option.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Gal, Omer& Dudnik, Elizabeth& Rotem, Ofer& Finkel, Inbar& Peretz, Idit& Zer, Alona…[et al.]. 2020. Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC. Journal of Oncology،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1188862
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Gal, Omer…[et al.]. Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC. Journal of Oncology No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1188862
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Gal, Omer& Dudnik, Elizabeth& Rotem, Ofer& Finkel, Inbar& Peretz, Idit& Zer, Alona…[et al.]. Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC. Journal of Oncology. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1188862
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1188862
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر